PRVL News and Press, Prevail Therapeutics Inc. From 04/29/20

Preclinical Data Demonstrate Potential of Prevail’s AAV Gene Therapy Approach to Slow or Halt Progression in Multiple Neurodegenerative Diseases Company Provides Design Overview for Planned Phase 1/2 PR001 PROVIDE and PR006 PROCLAIM Clinical Trials NEW YORK, April 29, 2020 (...

Inspire Medical Systems (NYSE: INSP ) initiated with Overweight rating and $74 (19% upside) price target at Piper Sandler. More news on: Inspire Medical Systems, Inc., Prevail Therapeutics Inc., Stereotaxis, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Design of PROPEL Phase 1/2 Clinical Trial for Parkinson’s Disease Patients with GBA1 Mutations to Be Presented Preclinical Data of PR001 for Parkinson’s Disease with GBA1 Mutations and PR006 for Frontotemporal Dementia with GRN Mutations to Be Presented NEW YORK, Marc...

Prevail Therapeutics (NASDAQ: PRVL ): FY GAAP EPS of -$2.22 beats by $0.74 . More news on: Prevail Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Dosing Initiated in PROPEL Phase 1/2 Trial of PR001 for Treatment of Parkinson’s Disease with GBA1 Mutations Preparations Underway to Initiate PROVIDE Phase 1/2 Trial of PR001 for Treatment of Type 2 Neuronopathic Gaucher Disease in Mid-2020 IND for PR006 for Treatment of...

NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA)...

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Buy rating and $69 (55% upside) price target at Citigroup. More news on: ACADIA Pharmaceuticals Inc., Alector, Inc., GW Pharmaceuticals plc, Healthcare stocks news, , Stocks on the move, Read more ...

NEW YORK, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announ...

Quick Take Passage Bio ( PASG ) intends to raise $126 million in an IPO of its common stock, per an amended registration statement . The company is advancing a pipeline of genetic treatment candidates for monogenic (single gene pair) central nervous system [CNS] conditions. PASG has yet...

Orphan Drug Designation Granted for Treatment of Gaucher Disease  Rare Pediatric Disease Designation Granted for Treatment of Neuronopathic Gaucher Disease NEW YORK, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or the...